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6/j.bLimited data are available on immunologic responses to primary H1N1 infection in patients with hematologic
malignancies. We present a prospective, case-surveillance study of such patients with real-time polymerase
chain reaction (RT-PCR) confirmed H1N1-influenza who presented to our institution between September
2009 and January 2010. Ninety-two patients presented with influenza-like symptoms, and 13 had H1N1 infec-
tion confirmed by RT-PCR, including 4 allogeneic stem cell transplant recipients (1 with acute myelogenous
leukemia, 1 with chronic lymphoblastic leukemia [CLL], 1 with non-Hodgkin lymphoma, and 1 with chronic
myelogenous leukemia), 5 patients withmultiple myeloma following autologous stem cell transplantation, 1 pa-
tientwithmultiplemyeloma perimobilization, 2 patients withNHL post chemotherapy, and 1 patient withCLL.
All 13 patients required hospitalization. Six (43%) were admitted to the intensive care unit (ICU), of whom 4
(67%) died. We evaluated B cell and T cell responses to H1N1 infection prospectively in these patients
compared with those in 4 otherwise healthy controls. Within 12 weeks of diagnosis, only 6 of 11 patients de-
veloped seropositive antibody titers asmeasured by hemagglutination-inhibition ormicroneutralization assays,
comparedwith 4 of 4 controls. H1N1-specific T cells were detected in only 2 of 8 evaluable patients compared
with 4 of 4 controls. H1N1-specific T cells were functional, capable of producing interferon g, tumor necrosis
factor a, and CD107amobilization. Furthermore, CD154was up-regulated on CD41 T cells in 3 of 4 controls
and 2 of 2 patients who had both B cell and T cell responses to H1N1. Post-H1N1 infection, 5 of 8 patients
developed seasonal influenza-specific T cells, suggesting cross-reactivity induced by H1N1 infection.
These data offer novel insights into humoral and cell-mediated immunologic responses to primary H1N1
infection.
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The emergence in Mexico of swine-origin influenza
A (H1N1) virus and its subsequent worldwide spread
led to the World Health Organization’s declaration of
a global pandemic in June 2009. Patients with a hemato-
logic malignancy are at risk from respiratory viral
infection [1].Data are limited on immunologic responses
to primary H1N1 infection and its clinical impact in pa-
tients with hematologic malignancies [2-5]. We present
the results of a prospective, case-surveillance study of
hematology-oncology patients and otherwise healthy
controls with real-time polymerase chain reaction
(RT-PCR)-confirmed H1N1 infection, focusing on the
humoral and T cell-mediated immunologic responses
to the H1N1 virus. Here, we demonstrate impaired
humoral and cellular immune responses to H1N1 infec-
tion in patients with a hematologic malignancy.
Biol Blood Marrow Transplant 17:632-639, 2011 633B and T Cell Responses to H1N1 Infection in Hematologic MalignanciesMETHODS
Case Identification and Clinical Data
Between September 1, 2009, and January 31, 2010,
all patients with hematologic malignancies and staff
members presenting with flu-like symptoms at our
institution were investigated for H1N1 by RT-PCR
[6]. Clinical, laboratory, and radiologic data were
collected prospectively.
Immunologic Investigations
Serum and peripheral blood mononuclear cells
(PBMCs) were collected preinfection and peri-
infection and within 12 weeks of diagnosis and cryo-
preserved. Anti-H1N1 antibodies were measured by
hemagglutination-inhibition and microneutralization
assays as described previously [7,8]. A titer of .1:32
by hemagglutination-inhibition or .1:160 by micro-
neutralization was defined as a protective antibody
response [9,10].
Assessment of the functionality of antigen-specific
CD81 andCD41Tcellswas performedby intracellular
cytokine staining for interferon (INF)-g and tumor
necrosis factor (TNF)-a and evaluation of CD154
expression and CD107a cytotoxicity as described
previously [11,12]. In brief, PBMCs were thawed and
stimulated for 24 hours with or without the H1N1
vaccine [A/California/07/2009(H1N1)v-like strain;
Baxter, Berkshire, UK] and seasonal influenza vaccine
[A/Brisbane/59/2007(H1N1)-, A/Brisbane/10/2007
(H3N2)- and B/Florida/30/2008-like strain; CSL Bio-
therapies, Hattersheim, Germany]. Brefeldin-A (10
mg/mL; Sigma-Aldrich, St Louis, MO) was added for
another 5 hours. PBMCs were washed and stained
with anti-CD3 and anti-CD8 antibodies, fixed/perme-
ablized (BD Biosciences, Oxford, UK), and stained
with anti–IFN-g and anti–TNF-a antibodies (all
from BD/Pharmingen, San Diego, CA). For CD154
and CD107a staining, PBMCs were stimulated for 18
hours with or without the H1N1 vaccine solution or
seasonal influenza vaccine. Cells were incubated for
6 hours with 0.7 mL/mL of monensin, anti-CD154,
and anti-CD107a antibodies (all BD/Pharmingen).
PBMCs were washed and stained with anti-CD3 and
anti-CD4 antibodies. A response was considered posi-
tive if the percentage of antigen-specific IFN-g–,
TNF-a–, or CD107a-expressing T cells was $2-fold
higher than background (unstimulated PBMCs) and
if there was a minimum of 0.05% antigen-specific
T cells (after subtracting the background).
All work was carried out under approval from the
local Ethics Committee, with informed consent
obtained from all participants.
Statistical Analysis
This study was a prospective, observational study.
One study endpoint was to prospectively analyze theassociations and outcomes for patients who were not
admitted to the intensive care unit (ICU) and survived
with those for patients who either died or were admit-
ted to the ICU. A second endpoint was to analyze and
compare the antibody and T cell responses to H1N1
infection in patients and controls. Clinical and labora-
tory endpoint data were analyzed using the two-sided
Fisher’s exact test (for noncontinuous variables) or
the Mann-Whitney U test (for continuous variables)
to compare the characteristics of evaluable patients
who required ICU admission versus those who did
not. Antibody andT cell responses in patients and con-
trols were compared using Fisher’s exact test, with
responses defined as positive or negative according to
the cutoff values defined earlier. All reported P values
are two-sided, with values#.05 considered to indicate
statistical significance. All calculations were performed
using SPSS version 17.0 (SPSS Inc, Chicago, IL).RESULTS
H1N1 Clinical Data and Outcomes
Between September 1, 2009, and January 31, 2010,
a total of 173 samples from 92 patients with a hemato-
logic malignancy were evaluated by RT-PCR for clin-
ically suspected H1N1 influenza. H1N1 infection was
confirmed in 13 patients. Seven staff members working
in the Hematology-Oncology Department (controls)
presenting with flu-like symptoms over the same time
period were screened for H1N1. H1N1 infection was
confirmed in 4 cases. Table 1 present data on the pa-
tients and controls with confirmed H1N1 infection.
The median age was 53 years (range 34-75 years) for
patients and 29 years (range 27-55 years) for controls.
Four patients had undergone a previous allogeneic
stem cell transplantation (allo-SCT), including 1
patient with chronic lymphocytic leukemia (CLL) on
day 153 after sibling reduced-intensity condit-
ioning (RIC) allo-SCT (patient 1), 1 patient with
non-Hodgkin lymphoma (NHL) on day 154 after
volunteer unrelated donor (VUD) RIC (patient 2), 1
patient with acute myelogenous leukemia (AML) 18
months post-VUD RIC (patient 3), and 1 patient
with chronic myelogenous leukemia (CML) 3 years
after myeloablative conditioning (MAC) allo-SCT
(patient 4). Patients 1 and2were receiving cyclosporine
at the time of H1N1 diagnosis. Five patients had
undergone a previous autologous SCT (auto-SCT)
formultiplemyeloma (MM) (patients 5-9), with widely
varying intervals from transplantation to contraction of
H1N1 (day 18, day 19, 4 months, 36 months, and 6
years post-transplantation). Three of the 4 patients
who had not undergone transplantation (patients 10,
11, and 13), had received chemotherapy or rituximab
within 1month of onset of influenza symptoms, includ-
ing 1 patient with MM peri-mobilization.
Table 1. Clinical Characteristics and Humoral and Cellular Immune Responses to H1N1 in Patients with Hematologic Malignancies and Control Cases with Confirmed H1N1 Infection
Antibody Response T Cell Response, % (CD4+/CD8+) (Post-H1N1 Infection)
By HI Assay By MN Assay
TNF-a/IFN-g/
CD107a Response
to H1N1
TNF-a/IFN-g/
CD107a Response
to Seasonal Flu
CD154
CD4+ T Cell
Response
to H1N1 OutcomePatient
Age,
Years Sex Diagnosis
Days
From SCT
Ongoing
Immunosuppressive
Agents Rituximab
Vaccinated
Against
H1N1 ICU
Pre-/Peri-
H1N1
Post-
H1N1
Pre-/Peri-
H1N1
Post-
H1N1
1 62 M Sibling RIC allo-SCT
for CLL
D+53 Cyclosporine A Y (4 doses on D-14,
D-6, D+1, D+8
of allo-SCT)
N Y <1:8 < 1:8 1:62 1:27 0 0 NA Recovered
2 44 M VUD RIC allo-SCT
for NHL
D+54 Cyclosporine A Y (4 doses on D-14,
D-6, D+1, D+8
of allo-SCT)
N N <1:8 <1:8 1:115 1:10 0 NA NA Recovered
3 55 M VUD RIC allo-SCT,
relapsed AML
18 months None N Y N <1:8 <1:8 1:27 1:250 0 0 NA Recovered
4 35 F VUD MAC
allo-SCT for CML
3 years None N N N <1:8 1:16,384 1:41 1:5120 NA NA NA Recovered
5 69 M Auto-SCT for MM D+8 None N N Y <1:8 1:64 1:45 1:3943 1.31/0.06 0.14/0 4.05 Died, H1N1-related
6 48 M Auto-SCT for MM D+9 None N N N NA 1:16,384 NA 1:5120 0.1/ 0.06 0.08/0.15 0.49 Recovered
7 64 M Auto-SCT for MM 4 months None N N Y 1:52 1:128 1:1846 1:1014 NA NA NA Died, H1N1-related
8 73 M Auto-SCT for MM 36 months None N N N <1:8 <1:8 1:199 1:10 0 0.02/0.06 NA Died, H1N1-unrelated
(progressive disease)
9 75 M Auto-SCT for MM 6 years Steroids N N N NA NA NA NA NA NA NA Recovered
10 67 F MM, etoposide mobilization NA None N N Y <1:8 1:512 1:84 1:5120 NA 0.08/0.39 0 Died, H1N1-related
11 51 M Post–renal
transplantation,
lymphoproliferative
disease
NA Tacrolimus Y (D+23
post-R-CVP)
N Y <1:8 <1:8 1:70 1:27 0 0.1/0.06 NA Died, H1N1-related
12 47 F CLL NA None N N Y <1:8 <1:8 1:78 1:10 NA NA NA Recovered
13 34 F Marginal zone NHL NA steroids Y (D+1 post-5th
cycle R-FMD)
N N 1:16 <1:8 1:162 1:10 0 0 0.03 Recovered
Control case
1 55 M None None None None Y N <1:8 1:512 1:14 1:3602 0.06/0 0.11/0.04 0.2 recovered
2 29 F Asthma None None None N N <1:8 1:64 1:10 1:765 0.01/0.1 0.05/0.03 0 recovered
3 29 M None None None None Y N NA 1:96 NA 1:842 0.05/0.05 1.56/0.09 0.1 recovered
4 27 F None None None None N N NA 1:256 NA 1:677 0.08/0.05 0.21/0.05 0.06 recovered
D indicates day; R-CVP, rituximab, cylcophospamide, vincristine, and prednisolone; SCT, stem cell transplantation; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; RIC,
reduced intensity conditioning; MAC, myeloablative conditioning; R-FMD, rituximab, fludarabine, mitoxantrone, and dexamethasone; NA, sample not available.
Shaded boxes represent positive responses. Due to sample availability issues, not all tests were performed in all patients and controls. Baseline antibody samples for controls 3 and 4 could not be collected because staff
were advised to stay at home.
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Table 2. Clinical Factors Associated with ICU Admission
ICU (N56) No ICU (N57) Control Cases (N54) P Value ICU vs No ICU
Median Age 63yrs (47-69) 48yrs (34-75) 29yrs (27-56) 0.391
Median days to treatment 2 (1-6) 3 (2-6) 3 (1-4) 0.445
CXR/ CT changes 6 1 0/1 0.005
GI symptoms at presentation 5 1 0/4 0.029
ECOG performance status 3 or more at presentation 4 0 NA 0.021
Median CRP at diagnosis (mg/L) 145 (64-169) 45.5 (19-134) NA 0.027
Median albumin at diagnosis (g/L) 23 (12-34) 31.5 (26-40) NA 0.063
Neutropenic at presentation (<1.0  10^9/ml) 3 2 0/1 0.59
IgG level <5.3g/L 2 3 NA 1
Serum creatinine >125micromol/L at diagnosis 4 1 0/1 0.103
Median K+ at diagnosis (mmol/L) 3.6 (2.9-4.5) 3.9 (3.5-4.5) NA 0.566
Other positive microbiological isolates 4 0 0 0.0202
ECOG indicates Eastern Cooperative Oncology Group; NA, not available.
Biol Blood Marrow Transplant 17:632-639, 2011 635B and T Cell Responses to H1N1 Infection in Hematologic MalignanciesReported clinical manifestations included cough
and coryzal symptoms in 13 patients (100%), fever in
12 (92%), myalgia in 10 (77%), and gastrointestinal
(GI) symptoms (vomiting or diarrhea) in 6 (46%). All
affected patients required hospitalization, as did 1
control, who was admitted for 3 days with exacerbation
of asthma. None of the controls required admission to
the ICU. In contrast, 6/13 patients (46%) were admit-
ted to ICU for a median of 35.5 days (range, 13-51
days) for multiorgan support, 4 of whom (67%) died
of an H1N1-related cause (Table 1). The requirement
for ICU support was significantly associated with the
presence of infiltrates on chest X-ray and/or computed
tomography scan, GI symptoms, and higher C-reactive
protein level at diagnosis (P\.05) (Table 2). All patients
were started on oseltamivir (Tamiflu; Roche Laborato-
ries, Basel, Switzerland) [13] at presentation. The me-
dian interval from onset of symptoms to initiation of
oseltamivir therapy did not differ significantly between
the patients who required ICU admission and those
who did not (2 days [range, 1-6 days] vs 3 days [range,
2-6 days];P5 .45). In 6/6 patients requiring ICUadmis-
sion, treatment with i.v. zanamivir (GlaxoSmithKline,
Brentford, Middlesex, UK) [14,15] was initiated after
a median of 9 days on oseltamivir therapy (range, 2-
40 days). Notably, of the 4 patients who died of an
H1N1-related cause, 3 had a diagnosis of MM early
post–auto-SCTor perimobilization.All allo-SCTrecip-
ients recovered from their infection and were discharged
home.
Humoral Immune Responses to H1N1
Table 1 presents results of the antibody response to
H1N1 infection recorded at baseline (preinfection/peri-
infection) and at followup (within 12weeks of diagnosis)
inpatients andcontrols.Atbaseline, 3of11 evaluable pa-
tients (patients 7, 8, and 13) and 0 of 2 evaluable controls
had a positive antibody response by hemagglutination-
inhibition assay (.1:32) or microneutralization assay
(.1:160). In 2 patients (patients 8 and 13), the positive
antibody responses by microneutralization assay at
baseline were weakly positive (1:199 for patient 8 and1:162 for patient 13) and not sustained. Two controls
(cases 1 and 3) and 1 patient (patient 3) contracted
H1N1 at 5, 7, and 10 days, respectively, after receiving
Pandemrix [Pandemic-A/California/07/2009(H1N1)
v-like strain] vaccine (Table 1).
At follow-up blood testing, only 6 of 11 evaluable
patients (patients 3, 4, 5, 6, 7, and 10) had a positive
antibody response by hemagglutination-inhibition
or microneutralization assay, compared with 4 of 4
controls (P 5 .10 for hemagglutination-inhibition
assay; P 5 .23 for microneutralization assay). The
median time from H1N1 diagnosis to assessment of
immunologic responses was 38.5 days (range, 9-64
days) in patients and 39.5 days (range, 12-120 days)
in controls (P 5 .65). Similarly, there was no signifi-
cant difference in the median time from diagnosis to
immunologic assessment in patients admitted to the
ICU and those not admitted (median, 39.5 days [range,
17-120 days] vs 38.5 days [range, 12-90 days]; P5 .71).
None of the 4 patients who had received rituximab
either as part of a fludarabine, cyclophosphamide,
and rituximab–conditioned allo-SCT (patients 1 and
2) or as part of a combination chemotherapy regimen
(patients 11 and 13) exhibited a seroprotective anti-
body response to H1N1 infection (Table 1). Of note,
no significant association was found between the pres-
ence of a seroprotective immune response and out-
come. Four of 7 evaluable patients who recovered
clinically had a positive antibody response, compared
to 4 of 5 who died (P 5 .58).
Cellular Immune Responses to H1N1
We analyzed CD81 and CD41T cell responses to
H1N1 infection in 4/4 controls and 9 patients for
whom PBMC samples were available. Table 1 presents
the maximum frequencies of CD41 and CD81 T cells
expressing either TNF-a, IFN-g, or CD107a in
PBMCs stimulated with H1N1 and seasonal influenza
vaccine, along with results for CD154 expression on
CD41 T cells after H1N1 stimulation. Values are
shown with the background (unstimulated cells) sub-
tracted. At baseline, there were no detectable CD81
636 Biol Blood Marrow Transplant 17:632-639, 2011P. Garland et al.or CD41 T cell responses to H1N1 in 9 patients and
2 controls in whom sufficient material were available
for analysis. At follow-up, CD81 or CD41 T cells
to H1N1 were detected in only 2 of 8 evaluable pa-
tients, compared with 4 of 4 controls. Figure 1 presents
fluorescent-activated cell sorting plots from a patient
with a robust T cell response to H1N1 infection (pa-
tient 6). We investigated the functional quality of
H1N1-specific T cells by flow cytometry analysis of
markers related to T helper cell 1 (TNF-a and IFN-g)
and degranulation/cytotoxicity (CD107a). CD154 ex-
pression also was assessed to identify activated CD41
T cells that might provide B cell help. H1N1-specific
T cells in 2 of 8 patients and 4 of 4 controls were capable
of TNF-a or IFN-g production or cytotoxicity as as-
sessed by CD107amobilization (Table 1). Two patients
and 4 controls had both B cell and T cell responses to
H1N1; CD154 was up-regulated on CD41 T cells in
5/6 of these cases, although the numbers were too
small to delineate any statistical association between
positive T cell and antibody responses.
Similarly, there was no association between induc-
tion of T cell responses to H1N1 and clinical outcome
postinfection. Of the 2 patients with a positive T cell
response to H1N1, one recovered (patient 6) and one
died (patient 5), although the sample size was too small
to allow us to draw any definitive conclusions.Figure 1. Functional characterization of CD81 andCD41T cell responses toHCellular Immune Responses to Seasonal
Influenza
We also looked for the presence of T cells against
seasonal influenza to assess the possibility of induction
of cross-reactive CD81 or CD41 T cells against sea-
sonal influenza and H1N1 after H1N1 infection. At
baseline, 0 of 8 evaluable patients and 1 of 3 evaluable
controls had a seasonal influenza-specific T cell
response. Post-H1N1 infection, 5 of 8 patients and 4
of 4 healthy controls developed a CD81 or CD41
T cell response against seasonal influenza (Table 1;
Figure 1). Contemporaneous nasopharyngeal aspirate
samples collected at the time of diagnosis of H1N1
infection were negative for other respiratory viridae
(including influenza A/B, parainfluenza 1/2/3, adeno-
virus, and respiratory syncytial virus) (data not shown),
suggesting that the T cell responses to seasonal influ-
enza were induced by the H1N1 infection in a cross-
reactive fashion.DISCUSSION
Our data demonstrate that H1N1 infection was
associated with impaired immune response and had
a severe course in patients with hematologic malignan-
cies, with a 46% rate of admission to the ICU.1N1 and seasonal influenza. Longitudinal data for patient 6 are presented.
Biol Blood Marrow Transplant 17:632-639, 2011 637B and T Cell Responses to H1N1 Infection in Hematologic MalignanciesFurthermore, the mortality in our cohort, in which
H1N1 was believed to be a contributing factor to
death, was 31%. The median age was 53 years for
patients and 29 years for controls, the latter being
more typical of the age group affected in previously
reported epidemiologic surveys of H1N1 [16,17].
The association between the prevalence of infiltrates
on chest imaging and requirement for mechanical
ventilation has been reported in other series [18],
although differences have been reported between
epidemiologic surveys and the observed patterns of ra-
diographic change (bilateral, patchy, or lobar) [19,20].
In our series, all patients who subsequently required
ICU admission had new lung infiltrates at diagnosis
that progressed on serial imaging. We also noted a
significant association of GI symptoms and subsequent
ICU admission. The unusually high prevalence of
diarrhea and/or vomiting as part of the presenting
complaint has been noted in previous H1N1 surveys.
Jain et al. [20] reported GI symptoms in 39% of cases
in their US survey, and although this level was not repli-
cated in recent Chinese data [19], this might have been
related to clinically dissimilar cohorts because of differ-
ing hospitalization practices.
By analyzing antibody responses in serum pre-
infection/peri-infection and at follow-up, we found
a baseline positive antibody response in 3 of 11
(27%) patients and 0 of 2 controls as measured by
hemagglutination-inhibition or microneutralization
assay.Previous studies have reported thepresenceof an-
tibody responses to H1N1 before vaccination in 16%-
30% of volunteers by hemagglutination-inhibition
assay [10,21] and in 31% by microneutralization assay
[10]. Interpretation of the baseline data in our cohort
is limited, however, because the measured responses
may not represent true preexisting antibody levels.
Although every effortwasmade to obtain serumas close
as possible to the time of H1N1 diagnosis, it is possible
that the infection might have been present before diag-
nosis for a sufficient time to elicit an antibody response.
Indeed, the median duration of symptoms before
diagnosis was 3 days. In addition, in 2 patients (8 and
13), the weakly positive baseline microneutralization
results seen in hematology-oncology patients were not
sustained. The same phenomenon was not seen with
the hemagglutination-inhibition assay. Two controls
and 1 patient contracted H1N1 after receiving the
Pandemrix vaccine. It is possible that the infection was
contracted before a protective immune response to
the vaccine was induced.
The kinetics of the antibody response to H1N1
infection in patients with malignancies is not known,
although in previous studies of H1N1 vaccination
in healthy controls, .90% seroconverted within 21
days of vaccination [9,22]. The immune response to
primary H1N1 infection appeared to be impaired in
hematology-oncology patients compared with the4 control cases. Although the number of evaluable
samples was too small to delineate statistical signifi-
cance between patients and controls, at follow-up,
only 6 of 11 patients had a positive antibody response
by hemagglutination-inhibition or microneutraliza-
tion assay, compared with 4 of 4 controls. Of note,
none of the 4 patients who had received ritxumab
had a seroprotective antibody response to H1N1
infection, suggesting that rituximab might negatively
affect the ability to develop a humoral response to
influenza antigens, as supported by previous studies
[23,24].
To assess the functional quality of the CD81 and
CD41Tcell response toH1N1,wemeasured intracel-
lular TNF-a and IFN-g secretion and CD107a mobi-
lization as indicators of effector T cell response and
cytotoxicity against the virus, as described previously
[12]. CD154 up-regulation was used to assess the inter-
action between CD41 helper T cells and B cells [11].
We found no detectable CD81 or CD41 T cell
responses to H1N1 at baseline. At follow-up, T cell
responses were detected in only 2/8 evaluable patients,
compared with 4/4 controls. These CD81 and CD41
T cells were capable of producing Th1 cytokines and
CD107a mobilization. Furthermore, CD154 was
up-regulated on CD41 T cells in nearly all cases
where both T cell and antibody responses to H1N1
were detected, supporting the fundamental role of
CD154 in the interaction between CD41 T cells and
B cells [11].
After H1N1 infection, T cell response to seasonal
influenza was detected in 5 of 8 patients and 4 of 4
healthy controls despite negative contemporaneousna-
sopharyngeal aspirate samples for other respiratory vir-
idae, suggesting that the T cell response to seasonal
influenza was induced by the H1N1 infection in
a cross-reactive fashion [25]. H1N1 virus and conven-
tional influenza strains differ in their hemagglutinin
sequences; however, internal proteins, such as M1
and NP, are well conserved among different influenza
strains [26]. Seasonal influenza vaccine does not pro-
duce cross-reactive antibodies to pandemic H1N1
[27,28], although in vitro data have shown up to 69%
cross-reactivity in CD81 T cell epitopes derived from
pandemic H1N1 and other seasonal influenza strains
[26]. Thus, it is possible that previous exposure to sea-
sonal influenza viruses, through either natural infection
or vaccination, led to the generation of these influenza-
specific T cells with cross-reactivity against H1N1; ex-
posure to pandemic H1N1 infection presumably then
led to expansion of these low-frequency cross-reactive
T cells. This possibility is supported by a recent study
demonstrating the existence of cross-reactive seasonal
and pandemic H1N1-specific T cells of similar avidity
with a memory phenotype in healthy controls [25].
We found no significant association between the
induction of a humoral or cellular immune response
638 Biol Blood Marrow Transplant 17:632-639, 2011P. Garland et al.and clinical outcome after diagnosis of H1N1 infection.
Three of 4 patients who died from an H1N1-related
cause had a positive antibody or cellular immune re-
sponse. It is possible that these immune responses
were overwhelmed by the virus by the time symptoms
developed and the diagnosis was made. Furthermore,
we have no information on the role of humoral and cel-
lular immunity against H1N1 in patients or controls
with subclinical H1N1 infection. Notably, 3 of 4 pa-
tients who died of an H1N1-related cause had a diag-
nosis of MM; all 3 patients had a positive antibody
response to H1N1, although the sample size is too
small to enable any definitive conclusions.
In conclusion, our data show that H1N1 infection
is particularly severe in patients with hematologic
malignancies [19,20,29]. Compared with otherwise
healthy controls with H1N1 infection, the humoral
and cellular immune responses to primary H1N1
infection appear to be impaired in patients with
hematologic malignancies. Cross-reactive T cells were
detected against H1N1 and seasonal influenza; how-
ever, whether these were protective against H1N1 in-
fection could not be determined. This article offers
insight into the clinical outcome of H1N1 infection in
the immunocompromised setting and provides novel
information on immunologic responses to primary
infection with this virus in patients with hematologic
malignancies and otherwise healthy controls. Given
the poor immunologic responses to H1N1 infection,
it is important to assess the protection afforded by vac-
cination in this vulnerable group of patients. To address
this question, we are currently examining the immuno-
genicity of the 2009 pandemic H1N1 vaccine in a large
cohort of hematology-oncology patients.ACKNOWLEDGMENTS
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